Reimbursement of pharmaceuticals: Reference pricing versus health technology assessment by Drummond, M. (Michael) et al.
ORIGINAL PAPER
Reimbursement of pharmaceuticals: reference pricing
versus health technology assessment
Michael Drummond • Bengt Jo¨nsson •
Frans Rutten • Tom Stargardt
Received: 23 July 2009 / Accepted: 10 August 2010 / Published online: 28 August 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Reference pricing and health technology
assessment are policies commonly applied in order to
obtain more value for money from pharmaceuticals. This
study focussed on decisions about the initial price and
reimbursement status of innovative drugs and discussed the
consequences for market access and cost. Four countries
were studied: Germany, The Netherlands, Sweden and the
United Kingdom. These countries have operated one, or
both, of the two policies at certain points in time, some-
times in parallel. Drugs in four groups were considered:
cholesterol-lowering agents, insulin analogues, biologic
drugs for rheumatoid arthritis and ‘‘atypical’’ drugs for
schizophrenia. Compared with HTA, reference pricing is a
relatively blunt instrument for obtaining value for money
from pharmaceuticals. Thus, its role in making reim-
bursement decisions should be limited to drugs which are
therapeutically equivalent. HTA is a superior strategy for
obtaining value for money because it addresses not only
price but also the appropriate indications for the use of the
drug and the relation between additional value and addi-
tional costs. However, given the relatively higher costs of
conducting HTAs, the most efficient approach might be a
combination of both policies.
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Introduction
In most jurisdictions, obtaining value for money from use of
pharmaceuticals is seen as an important policy objective,
since it is important in maximising the health gain from the
use of health care resources. A range of policies exists,
including generic substitution, patient co-payments and price
controls. Two policies have become more popular in recent
years: reference pricing and health technology assessment.
Under reference pricing, drugs that are judged to be
similar are ‘clustered’ and a single level of reimbursement
(i.e. the reference price) set for the cluster, usually based on
the price of the cheapest drug in the group or on some
average of existing prices [14]. The manufacturers of the
various drugs in the cluster are free to charge a price higher
than the reference price, but this tends not to be the case
because of the fear that patients may be deterred by the
higher co-pay. Since this severely restricts the possibility to
compete, in some cases, it may not be profitable to launch a
new product on the market. Therefore, the incentive to the
manufacturer is to set a price close to the reference price.
Some reference pricing schemes only cluster drugs with the
same chemical entity, but others, such as the schemes
operating in The Netherlands and in Germany, cluster
drugs which are deemed to be therapeutically equivalent. It
is these latter schemes that are of interest in this paper.
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Under health technology assessment, reimbursement is
granted if the incremental cost-effectiveness ratio, com-
paring the drug with other relevant alternatives, is within
the acceptable range. Since the price of the drug is an
important driver of the cost-effectiveness ratio, there is an
incentive for the manufacturer to set a price that results in
an acceptable cost-effectiveness ratio. Since a drug cannot
be cost-effective in itself, but only in relation to a defined
comparator and for a defined indication, HTA can be
used to restrict reimbursement within the licensed indica-
tions [24].
In principle, both policies relate the value of the drug to
its price but do so in slightly different ways. Normally, the
assessments of comparability made under reference pricing
are not as detailed as those made under technology
assessment. The focus is on relative clinical effectiveness,
defined fairly narrowly, rather than relative value. Also,
health technology assessment is more flexible, since it
allows the consideration of cost-effectiveness by indication
(for example, first line or second line), or patient sub-
group, whereas reference pricing sets a single reimburse-
ment level for the drug in all its licensed indications.
On the other hand, health technology assessment, if
performed correctly, can be very resource intensive. In
addition, considerable time and effort may be consumed in
demonstrating minor differences between products that,
whilst being present, may not justify a difference in the
amount reimbursed. In such cases, a simple clustering
approach would be less resource intensive.
Several Western European countries have adopted one
or other of these policies at various points in time. The
ideal policy would be one that provides sufficient rewards
(to manufacturers) for innovation, whilst securing value for
money for the health care system. The objective of this
paper is to compare and contrast reference pricing with
health technology assessment, with a view to identifying
the pros and cons of each.
Methods
The general approach was to focus on decisions about initial
price and reimbursement status for innovative drugs. Four
countries were considered: Germany, the Netherlands,
Sweden and the United Kingdom. Germany has had a ref-
erence pricing system for many years, based on therapeutic
equivalence. When being introduced in 1989, German ref-
erence pricing initially affected all pharmaceuticals—with
or without patent protection. Later, patented, pharmaceuti-
cals, with marketing authorisation subsequent to 1st January
1996, were excluded from reference pricing. This was
partly revoked by an amendment in 2004. If a patented drug
is considered a me-too drug and the respective original drug
is already off-patent, both drugs are included in the ref-
erence pricing scheme [23]. A newly formed institute
(IQWiG) is undertaking health technology assessments.
From its formation in 2005, IQWiG’s assessment of drugs
was restricted to ‘‘benefit assessment’’, which can be
interpreted as relative effectiveness. However, with the
health reform act of 2007, the German legislator extended
the scope of the IQWiG and is planning to introduce a
reimbursement limit (i.e. a ‘maximum price’, linked to
results from economic evaluations (i.e. health technology
assessments) for drugs that are not subject to reference
pricing.
The Netherlands has also operated a reference pricing
system since 1991, based on therapeutic equivalence. In
addition, health technology assessments are undertaken for
drugs that are, a priori, considered to be sufficiently inno-
vative to justify a premium price.
Sweden operated a reference pricing policy for drugs of
chemical equivalence between 1993 and 2002. However, it
was replaced by a drug substitution scheme, where the
pharmacies select the available drug with the lowest price
in the class. In the same year, the Pharmaceutical Benefit
Board (LFN) was established. The LFN (now called the
Dental and Pharmaceutical Benefits Agency-TLV) decides
on the reimbursement of new drugs based on health tech-
nology assessments. The system is product oriented, but
TLV can restrict reimbursement to specific indications or
for a limited time whilst more data are collected. It also
reviews groups of drugs defined by ATC code. The TLV
also decides on which drugs are included in the generic
substitution scheme and keeps a record of their prices.
The United Kingdom operates the health technology
assessment policy, but does not operate reference pricing.
In England and Wales, the National Institute for Health and
Clinical Excellence (NICE) appraises those new drugs
thought likely to have a major clinical or economic impact
on the NHS. In Scotland, the Scottish Medicines Consor-
tium (SMC) undertakes health technology assessments of
all new drugs. The various technology appraisals under-
taken in the United Kingdom vary in their cost and com-
plexity. However, although the United Kingdom has no
experience with reference pricing, it is included in this
study since it provides an example of what can be achieved
by the extensive use of HTA in decisions about drug
reimbursement [7].
We considered innovative new drugs in four clinical
areas, comparing and contrasting the outcomes (in price
and reimbursement status) in the four countries. The areas
considered were as follows:
1 hyperlipidaemia: where there are both new and existing
statins, plus other new drugs for reducing lipid levels
(e.g. ezetmibe);
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2 diabetes: where there are new insulin analogues and
long-acting insulin;
3 rheumatoid arthritis: where there are several new bio-
logic agents;
4 schizophrenia: where there are several new atypical
neuroleptics.
These four disease areas were chosen primarily because
they are quite important, yet quite diverse. Also, it was
known that decisions on pricing and reimbursement had
recently been taken in the four countries of interest, either
through reference pricing or health technology assessment.
Most drugs in these classes are also prescription drugs,
which means that they are included in the reimbursement
system. However, one of the rheumatoid arthritis drugs is a
hospital product and hence not included in all cases. Ide-
ally, it would be preferable to study drugs in all disease
areas, but we have no reason to believe that the reim-
bursement issues relating to drugs in these 4 areas are
atypical of those for drugs more generally.
Results
Hyperlipidaemia
In the four countries being studied, the older statins,
including pravastatin and simvastatin, are now off-patent.
Therefore, the analysis focussed on atorvastatin and two
new cholesterol-lowering agents, rosuvastatin and ezetim-
ibe. (Ezetimibe is available both as a single agent and in
combination with simvastatin.)
Prices
Table 1 shows the current prices of the various drugs in
the four countries, obtained from the following sour-
ces (http://www.medicijnkosten.nl, http://www.aponet.de
, http://www.ppa.org.uk, http://tlv.se). The prices quoted are
those applying on 1st March 2008 and are ex-pharmacy
prices, reflecting the full cost of the products to the health
care system. Therefore, when comments are made below
about the differences in prices between the four countries,
these could reflect differences in pharmacy margins as
well as differences in the amount received by the manufac-
turer in each case. Also, the cross-country price comparisons
are dependent on the currency conversion rate used at the
time of the study.
For statins, it can be seen that the prices of all the drugs
are higher in Germany than the other three countries.
However, because atorvastatin has been clustered with other
statins under the reference price scheme (see below), the
reimbursement level is much lower than the price. This
implies that patients prescribed atorvastatin would face large
co-payments or would have to switch to other statin agents.
Rosuvastatin was not marketed in Germany at the time of the
study. There could be many reasons for this, but it is likely
that the low reference price for statins is a major factor in the
company’s decision not to launch. Ezetimibe is not clustered
with any other drugs, being from a different class.
Reimbursement status
In Germany, statins, being one of the first four reference
pricing groups formed after the amendment of 2004, are
clustered in one reimbursement group including branded
original drugs, their generic copies and patented drugs
considered me-too (a so-called jumbo group). This decision
was made based on a report by the Institute for Quality
and Efficiency in Health Care (IQWiG), which did not
find significant evidence for the superiority of atorvastatin
over other statins in respect of efficacy or side-effect
profile [10].
In the Netherlands, the statins are clustered, along with
ezetimibe and ezetimibe/simvastatin. Although the prices
Table 1 Prices of cholesterol-
lowering drugs (€)
Prices shown are off pharmacy
prices. If the amount reimbursed
is lower than the price, this is
shown in parentheses. The
patient pays the difference
N/A not available
a Exchange rate: SEK
9.50 = 1€
b Exchange rate: £0.70 = 1€
c Combination treatment not
available. Prices based on the
individual drugs
Agent Germany The
Netherlands
Swedena United
Kingdomb
Atorvastatin 10 mg 1.29 (0.65) 1.03 0.91 0.92
Atorvastatin 20 mg 1.84 (0.81) 1.47 1.33 1.26
Atorvastatin 40 mg 2.13 (1.06) 1.82 1.78 1.44
Ezetimibe 10 mg 1.88 1.54 1.26 1.34
Ezetimibe/simva 10/20 mg 2.40 1.87 1.30c 1.70
Ezetimibe/simva 10/40 mg 2.73 2.15 1.39c 1.99
Ezetimibe/simva 10/80 mg 2.86 2.26 1.46c 2.13
Rosuvastatin 5 mg N/A 0.74 1.02 0.92
Rosuvastatin 10 mg N/A 1.06 0.91 0.92
Rosuvastatin 20 mg N/A 1.57 1.34 1.33
Rosuvastatin 40 mg N/A 1.90 1.89 1.52
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of the drugs differ, the patient receives full reimbursement,
which is an exception under reference pricing. Since 2005,
health insurers are allowed to impose restrictions on the
delivery of statins to their insured, and nowadays more
than 70% of insured can only get reimbursement for the
lowest priced generic unless the prescribing physician
states that a higher priced statin must be delivered for
medical reasons.
In Sweden, atorvastatin is generally available for treat-
ment of hyperlipidaemia, since the reimbursement decision
was made before the patent expired for simvastatin
(Zocor). The use of both rosuvastatin and ezetimibe is
restricted to patients who have tried generic simvastatin but
for different reasons need another product. For example,
ezetimibe is only reimbursed for patients where other
treatment options are not available (e.g. where statins are
not suitable) and as add-on therapy to statins in patients
with inadequate control meeting the following criteria
(established coronary artery disease, other atherosclerotic
disease, type 2 diabetes, hereditary hypercholesterolaemia
and multiple risk factors).
Prices for statins fell on average by 70% when the patent
expired for simvastatin (Zocor) in February 2003.
An indirect effect of this was that the sales of atorvastatin
and pravastatin were reduced. It is thought that 10% points
of the 70% average reduction in cost per daily defined dose
(DDD) for statins were due to this indirect effect. The
patent expiration probably also had a strong negative effect
on the sales of rosuvastatin. By 2006, simvastatin had 85
per cent of the market in terms of volume (doses or patients
treated) [8].
Recently, lipid-lowering medicines were the subject of
a review conducted by the TLV. As a result of this, the
branded versions of simvastatin and pravastatin lost their
reimbursement status, as did branded atorvastatin (10 mg
strength) and rosuvastatin (5 mg strength). Atorvastatin
and rosuvastatin are reimbursed in other strengths only if
generic simvastatin has been tried and the patient has not
achieved the treatment objectives. Ezetimibe is reim-
bursed if generic simvastatin has been tried and the
patient has not achieved the treatment objectives, or it has
been established that the patient cannot tolerate statins
[25].
In the United Kingdom, statin therapy was approved by
NICE (in England and Wales) for primary prevention in
adults with a 20% or greater 10-year risk of CVD. How-
ever, therapy should usually be initiated with a drug with a
low acquisition cost, taking account of the required daily
dose [16]. In Scotland, the SMC approved rosuvastatin for
general use, but restricted the use of ezetimibe and
ezetimibe/simvastatin to patients who are unable to reach
target levels of cholesterol, despite titration of their exist-
ing statin.
Diabetes
Until recently, the treatment of diabetes involved the use of
insulin and oral antidiabetic drugs that have been on the
market for several years. However, several new drugs have
become available, particularly for the treatment of type 2
diabetes.
The focus here was on the insulin analogues (detemir,
glulisine, lispro, aspart and glargine). Detemir and glulisine
are long-acting formulations that provide a more consistent
release during the day, thereby mimicking natural basal
insulin release. The prolonged absorption profile, with no
pronounced peaks over 24 h, allows for once-daily dosing.
Furthermore, since they do not require resuspension prior to
administration, because of their soluble formulation, they
have the potential to reduce inter-and intra-user variability.
Aspart, glulisine and lispro are rapid-acting analogues
that mimic the physiological meal-time insulin profile
much more closely than unmodified human insulin injec-
tions can. Peak plasma concentrations are reached about an
hour after injection, with absorption finishing within 3–5 h.
Accordingly, they control the rise in blood glucose con-
centrations better after meals, thereby reducing the risk of
hypoglycaemia after food absorption has ceased.
Prices
Table 2 shows the current prices of the insulin analogues in
the four countries. Again, the prices in Germany are higher
than in the other countries. However, use of the new
products has been restricted as the result of a technology
assessment report.
Reimbursement status
In Germany, IQWiG undertook an assessment of rapid-
acting insulin analogues for the treatment of type 2 diabetes
[9]. The literature search initially gave 1,017 hits, but these
were reduced to 19 publications after further scrutiny by
the reviewers. In the end, only seven studies were used in
the assessment, as IQWiG decided to concentrate on ran-
domised controlled trials only. In five of the studies, insulin
lispro was compared with human insulin, and in the other
two, insulin glulisine was compared with human insulin. In
all cases, the drugs were added to basal long-acting insulin.
No relevant study was published on insulin aspart.
All the clinical trials that met the inclusion criteria were
over a relatively short period (5.5–12 months), which meant
that they could not consider the effect of rapid-acting insulins
analogues on diabetic complications or overall mortality.
The analysis had a very narrow clinical focus, limited to
assessments of hypoglycaemic rate and stability of the blood
sugar level. There were only limited measurements of
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illness-related quality of life and none of patient satisfaction.
Within the clinical trials included in the assessment, one
would not expect much difference between the analogues
and human insulin. Indeed, no differences were found. The
question is whether there are important and relevant differ-
ences in patient satisfaction, quality of life and convenience
of use that were not examined in the study.
Based on the report, the rapid-acting insulin analogues
aspart, glulisine and lispro were excluded from reim-
bursement by the Federal Joint Committee (G-BA) for
patients with diabetes mellitus type 2, as long as cost of
treatment with an rapid-acting insulin analogue was more
expensive than cost of treatment with human insulin.
Exceptions were made for diabetes type 2 patients that are
allergic to human insulin and for patients that could not be
treated adequately with human insulin. Manufacturers
reacted by offering large rebates to the sickness funds,
whilst keeping the retail prices above the threshold. As the
IQWiG assessment of long-acting insulins analogues has
not been finished yet, no reimbursement limit has been set
for determir and glargine.
In the Netherlands, insulin detemir and glargine are in
one cluster and are of equal price. Insulin aspart and lispro
are in another cluster, with a lower price. In both cases, the
manufacturers have set the price equal to the reference
price, so there are no patient co-payments.
In Sweden, both the rapid-acting insulin analogues,
glulisine and lispro, are reimbursed without restrictions.
The long-acting insulin glargine is also reimbursed without
restrictions, but determir is reimbursed only for patients
with type 1 diabetes. Insulins are excluded from the normal
co-payment system in Sweden, as they are medications for
a chronic disease. Co-payment is linked to total drug
expenditures during a 12-month period and involves a
deductable and coinsurance. Maximum co-pay is 200 Euro
for a 12-month period, which means that most patients on
chronic medications have ‘‘free drugs’’.
In the United Kingdom, insulin glargine was considered
by NICE (for England and Wales). It was recommended as
a treatment option for people with type 1 diabetes. How-
ever, the Institute considered that the cost-effectiveness of
insulin glargine was less well established for people with
type 2 diabetes, principally because of the lower frequency
of hypoglycaemic episodes among this group and conse-
quently the relatively limited scope for improvement.
Therefore, it recommended that insulin glargine should be
considered only for those people with type 2 diabetes who
(1) require assistance from a carer or health care profes-
sional to administer their insulin injections, (2) find their
lifestyle is significantly restricted by recurrent symptomatic
hypoglycaemic episodes or (3) would otherwise need
twice-daily basal insulin injections in combination with
oral antidiabetic drugs [17].
In Scotland, insulins detemir and glargine have been
assessed by the SMC. Insulin detemir was accepted for
restricted use, targeted on patients attempting to achieve
better hypoglycaemic control. Insulin glargine was also
accepted for restricted use, targeted on patients who are at
risk or experience unacceptable frequency and/or severity
of nocturnal hypoglycaemia on attempting to achieve better
hypoglycaemic control during treatment with established
insulins. It was also considered acceptable as a once-daily
insulin for patients who require carer administration of
their insulin. Routine use in type 2 diabetes was not sup-
ported for either insulin detemir or insulin glargine.
Rheumatoid arthritis
After many years with no new therapies, there have been
several new drugs for RA in the last few years. This analysis
focussed on the first TNF alpha blockers adalimumab,
etanercept and infliximab. All the three are indicated when
the patient has failed two or more DMARDs (disease-
modifying arthritis drugs), one of which should be metho-
trexate. In the case of infliximab, the drug should be used
in addition to methotrexate. The TNF alpha blockers rep-
resent a breakthrough in therapy for many patients but are
expensive.
Table 2 Prices of insulin
analogues (€)
Prices shown are off pharmacy
prices. If the amount reimbursed
is lower than the price, this is
shown in parentheses. The
patient pays the difference
a Exchange rate: SEK
9.50 = 1€
b Exchange rate: £0.70 = 1€
Agent Germany The
Netherlands
Swedena United
Kingdomb
Glulisine inj. 100 E/ml patron 3 ml 13.82 7.17 8.19 8.42
Glulisine inj. 100 E/ml WWSP 3 ml 13.82 7.89 8.19 9.01
Insulin lispro 100 E/ml patron 3 ml 13.83 7.17 7.76 8.42
Insulin lispro 100 E/ml WWSP 3 ml 14.22 7.89 8.70 8.42
Detemir penfill inj. 100 E/ml patron 3 ml 15.77 11.85 12.80 11.15
Detemir penfill inj. 100 E/ml WWSP 3 ml 16.12 12.37 13.11 11.15
Glargine inj. 100 E/ml patron 3 ml 17.26 11.85 12.80 11.15
Glargine inj. 100 E/ml WWSP 3 ml 17.62 12.37 13.11 12.01
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Prices
Table 3 shows the prices for the TNF alpha blockers in the
four countries. Prices for all three drugs are substantially
higher in Germany. In the Netherlands, infliximab is not
included in the reference pricing scheme as it is a hospital-
based product. In this case, health insurers reimburse 80%
of the costs of a specific list of very expensive hospital
drugs, leaving only 20% to be paid out of the hospital
budget. However, this regime is conditional on the moni-
toring of the performance (i.e. cost-effectiveness) of these
drugs in practice. Continuation of the additional financing
depends on the results of this monitoring after 3 years [2].
Reimbursement status
In Germany, there is no reimbursement limit for these
drugs, as reference pricing does not include patented
innovations and the amendments made to drug regulation
policy in 2007 have not been implemented yet. Only if
the first active ingredient of a potential group of drugs
loses patent protection, a reference group will be formed.
However, other regulatory instruments e.g. physician drug
budgets and co-payments may influence price setting of
manufacturers indirectly [3].
In the Netherlands, adalimumab and etanercept are in
the same cluster and can be used according to licensed
indications. Infliximab is not in the cluster since, being
delivered by intravenous infusion, it is a hospital-based
product. Patients can receive this drug without co-payment
at the hospital. Adalimumab and etanercept are reimbursed
without major restrictions. Sweden has among the highest
use of TNF inhibitors in Europe, comparable only to
Norway. The use is more than twice as high as in Germany
[12, 13].
In the United Kingdom, all three drugs have been
reviewed by NICE. Although there were some small dif-
ferences in the estimated cost-effectiveness of the different
agents, the conclusion of the appraisal was that all drugs
could be used in line with their licensed indications. No
additional restrictions were initially applied, although a
revision of the guidance in October 2007 stated that
treatment should only be continued if there is an adequate
response at 6 months following initiation of therapy [19].
Atypicals for schizophrenia
In recent years, several new drugs have become available
for the treatment of schizophrenia. Although technically
belonging to different classes, they go under the common
term ‘atypicals’. These drugs include risperidone, olanza-
pine, quetiapine and aripiprazole. Although not particularly
expensive for a course of therapy, they are a much higher
price than drugs that have been available for many years,
such as haloperidol.
Prices
Table 4 shows the prices of the various drugs in the four
countries. The prices are fairly similar for The Netherlands,
Sweden and the United Kingdom, but higher for Germany.
Reimbursement status
In Germany, there is no reimbursement limit for any of
these drugs. In the Netherlands, all atypicals are in the same
cluster. Prices are fairly similar, so patient co-payments
are minor. In Sweden, all the drugs are reimbursed without
restrictions. In the United Kingdom, NICE reviewed the
first three atypicals: quetiapine, olanzapine and risperidone.
Whilst noting that there were differences in the range of
evidence for the different products, it did not distinguish
between them. It recommended the use of all atypicals first
line [18].
In Scotland, the SMC allowed general use of aripip-
razole. It has not reported on the use of the other atypicals,
but use of the drugs is in line with the NICE recommen-
dations. In addition, both NICE and the SMC have con-
sidered the use of the atypicals in related conditions, such
as bipolar disorder.
Table 3 Prices of TNF a Blockers (€)
Agent Germany The
Netherlands
Swedena United
Kingdomb
Adalimumab inj 40 mg/ml or 50 mg/ml WWSP 0.8 ml 960 576 604 511
Etanercept 50 inj. mg/ml WWSP 1.0 ml 456 288 302 226
Infliximab 100 mg 868 N/A 574 600
Prices shown are off pharmacy prices. If the amount reimbursed differs, this is shown in parentheses. The patient pays the difference
N/A not available
a Exchange rate: 9.50 = 1€
b Exchange rate: £0.70 = 1€
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Discussion
The main advantage of reference pricing is that it is rela-
tively easy to implement on a comprehensive basis, cov-
ering all new and existing drugs. (Our focus here was on its
application to new drugs.) It is also probably less costly to
administer than health technology assessment, although an
evaluation in Norway, undertaken prior to the abandon-
ment of the policy, showed that the costs outweighed the
savings [12]. Also, behind the Norwegian decision to
replace reference pricing with generic substitution was an
evaluation that the system was complicated to administer
and did not produce significant gains after the initial price
reductions. Experience shows that, in general, the policy is
effective in forcing prices down to the reference price, but
manufacturers have no incentives for further price reduc-
tions, or to consider which indications for their drug would
be most cost-effective.
However, the main issues with reference pricing relate
to how it is applied in practice. Beyond its use for drugs
containing the same molecule, the key question is that of
how similar do different drugs have to be in order to be
clustered and what level of analysis precedes clustering?
Also, in the absence of health technology assessment, what
method should be used to set the reference price for a new
cluster? (In The Netherlands, the price is set relative to the
price in other countries).
In addition, under reference pricing, all the licensed
indications for a drug are tacitly accepted, whereas it may
be more cost-effective in certain indications, or for par-
ticular patient subgroups. Finally, setting reference prices
for some drugs might lead to price increase for drugs not
subject to reference pricing.
In principle, health technology assessment allows a
consideration of all the costs and benefits of innovative
drugs in a wide range of indications and patient subgroups.
It is also more flexible. For example, recommendations can
be revised as more evidence becomes available, or reim-
bursement can be made conditional on the gathering of
additional data. In addition, value for money is explicitly
addressed, and decision-makers can set their threshold of
willingness-to-pay for innovation.
The main problems with health technology assessment
relate to the difficulties of implementing the policy on a
comprehensive basis and the difficulties of conducting
appraisals of sufficient quality. In particular, if every new
drug were to be assessed for cost-effectiveness, in many
settings this assessment would be, of necessity, very cur-
sory, since the resources would not be available to under-
take all the assessments thoroughly. Therefore, it may
make sense to prioritise the assessments towards those
innovative compounds that are the first in their class. Then,
if similar drugs are launched at a similar price, it probably
does not make sense to undertake a thorough assessment.
A natural experiment is taking place in the United
Kingdom with respect to the thoroughness of health tech-
nology assessments. In Scotland, the procedure is not very
resource-intensive and, as a consequence, every new drug
can be considered. In England and Wales, the standard
assessments undertaken by NICE (called Multiple Tech-
nology Assessments or MTAs) are very detailed, but the
recently introduced single technology appraisals (STAs)
are closer to the Scottish model. Both models incorporate a
submission, of a technology assessment, by the manufac-
turer. The main difference surrounds the detail of the
independent evaluation of the evidence on effectiveness
and cost-effectiveness. Therefore, a subsidiary question is
whether different types of appraisals give rise to different
decisions. This is beginning to be studied the general
conclusion being that the broader decisions, about whether
a given drug is recommended for use, are fairly similar.
However, some of the more detailed decisions, about the
indications for use of the drug, or the most suitable patient
populations, sometimes differ [1, 4].
A related issue is that of whether the decision-making
body provides funding for an independent group to
undertake the assessment. In the Netherlands and Sweden,
the evaluation is undertaken by the Health Care Insurance
Table 4 Prices of atypicals for
schizophrenia
Prices shown are off pharmacy
prices. If the amount reimbursed
is lower than the price, this is
shown in parentheses
a Exchange rate: SEK
9.50 = 1€
b Exchange rate: £0.70 = 1€
Agent Germany The
Netherlands
Swedena United
Kingdomb
Risperidone 1 mg 2.12 0.99 0.84 0.82
Risperidone 2 mg 3.55 1.77 1.58 1.63
Olanzapine 2.5 mg 3.14 1.78 1.87 1.70
Olanzapine 5 mg 4.53 2.17 2.73 2.46
Quetiapine 25 mg 1.44 0.74 0.72 0.82
Quetiapine 100 mg 2.37 1.52 1.37 2.69
Quetiapine 200 mg 3.89 2.54 2.09 2.69
Aripiprazole 15 mg 8.73 4.18 4.51 5.05
Aripiprazole 30 mg 13.88 8.38 8.36 10.38
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Board (CvZ) and TLV, respectively. In Germany, the
assessments are undertaken by IQWiG. In the United
Kingdom, both NICE and the SMC commission an external
assessment. Clearly, in all systems much depends on the
quality of the manufacturer’s submission and the rigour of
the evaluation.
The ways in which health technology assessment is
applied vary from place to place. The approaches to health
technology assessment in the United Kingdom largely
follow the methodological guidelines laid down by NICE
[20], which encourage the use of decision-analytic mod-
elling. However, in Germany, IQWiG’s initial methods
guidance placed a major emphasis on the clinical evidence
obtained from randomised controlled trials [6]. However,
subsequent versions of the guidance have suggested an
expanded role for modelling [11]. This begs the question as
to whether there could be more harmonisation of the
methods of health technology assessment in Europe [22].
Any impact of reference pricing and health technology
assessment on value for money will be apparent in the
observed price and reimbursement status of the various
drug groups in the four countries. With respect to pricing,
the impact of reference pricing is only substantial when
there are wide differences in the prices of drugs in a given
cluster. Since the focus of this paper was on the initial price
of innovative drugs, wide differences were not generally
observed, since the manufacturers of similar drugs tend to
price them at a similar level in a given market. However, as
was seen in Germany, as soon as one of the drugs in the
cluster becomes generic, reference pricing can have a
major impact. Normally, one would expect the price of all
drugs in the cluster to fall to the level of the reference
price. However, in the case of the drug groups studied here,
the manufacturers maintained their original price. In the case
of atorvastatin, this led to increased patient co-payments;
in the case of insulin analogues, the price was maintained
by use of a subsidy.
The precise impact of health technology assessment on
prices is hard to assess, and no clear pattern could be
observed in the cross-country price differences reported in
this paper. In theory, one would expect the manufacturer to
propose a price that will result in the drug being cost-
effective when it is subjected to an HTA. It is not normal
for the HTA to be a vehicle for price negotiation in most
countries, although there are examples of manufacturers
offering deals that amount to price reductions as part of the
discussions surrounding the HTA. Many of these discus-
sions do not reach the public domain, the payment by
results scheme for bortezomib (Velcade) in the United
Kingdom being an example of one that did [21].
With respect to reimbursement, the focus of reference
pricing is on establishing the reimbursement level for the
cluster. As mentioned earlier, in the absence of a generic,
or otherwise inexpensive drug, it is unclear how this level
is set. On the other hand, the flexibility that exists under
the policy of health technology assessment, where reim-
bursement can be conditional or limited to certain indica-
tions or patient subgroups, is clearly very important in the
quest to secure more value for money. Most of the rec-
ommendations following health technology assessments do
not result in straightforward acceptance or rejection of the
new drug. Rather, they mostly limit the use of the drug to
the indications or patients in which it is most cost-effective.
Many of the recommendations of bodies like NICE point to
the need for future research [15]. Therefore, the recom-
mendations following HTAs potentially reward innovation,
whilst paying attention to value for money. This may
become even more apparent if value-based pricing
schemes, such as that proposed in the United Kingdom,
are implemented. Under such schemes, the price of a drug
would be based on the value it adds in each individual
indication, as demonstrated through technology appraisals
[5].
Conclusions
Reference pricing alone does not represent a viable policy
for obtaining value for money from pharmaceuticals.
Health technology assessment represents a much better
approach, for the reasons discussed earlier. In particular, it
incorporates an explicit assessment of the value for money
of new drugs, in various indications and patient subgroups.
Reference pricing may have a supporting role, since it
provides an approach for making decisions about the
pricing and reimbursement of those drugs which are ther-
apeutically equivalent to other, existing drugs, and for
which it would be a waste of resources to conduct a health
technology assessment. However, it is not the only such
policy. Encouragement of price competition and generic
substitution would be others. A combination of reference
pricing and price competition was introduced in Germany
in 2006. Drugs priced below 30 per cent of the reference
price are exempted from regular co-payments. It was
expected that this would trigger price competition and
enable the regulator to set lower reference prices in return.
However, long-term effects of the policy change have not
yet been evaluated.
It could be that a dual policy is emerging, whereby the
primary policy for obtaining value for money from new
drugs is based on health technology assessment, supported
by reference pricing or another approach. A good example
would be the situation in The Netherlands, where innova-
tive drugs are subjected to health technology assessment, in
order to assess whether they should be placed in a new
cluster and to establish the reference price for any new
270 M. Drummond et al.
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cluster. Germany is also heading in this direction, as it
introduced maximum reimbursement prices for drugs that
are not subject to reference pricing based on HTA.
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